- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00902291
A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
A Global, Multi-center, Open-label, Phase 2 Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
A disease assessment will be performed at study week 8 (± 3 days) by the investigator. The assessment will be based both on changes in clinical symptoms, and radiographic images. Subjects without evidence of disease progression may continue to receive treatment based on their original treatment assignment until disease progression or intolerability. Disease assessments will be performed every 8 weeks during the extended period. A safety follow-up visit will occur 4 weeks after the last dose infusion of AGS-1C4D4 and/or gemcitabine.
Post-Treatment: Subjects terminating from protocol therapy for reasons unrelated to documented disease progression will be followed by telephone contact every 2 months until they begin a new anticancer therapy, their disease progresses, they die, become lost to follow-up or withdrawal consent for further follow-up, whichever of these events occurs first.
Overall survival: All subjects will be followed by telephone contact every 2 months until death, loss to follow-up, or withdrawal of consent, whichever of these events occurs first.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Alberta
-
Edmonton, Alberta, Canadá, T6G 1Z2
- Cross Cancer Institute
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8V 5C2
- Juravinski Cancer Centre
-
Toronto, Ontario, Canadá, M4N 3M5
- Sunnybrook Health Sciences Centre
-
-
-
-
-
Barcelona, España
- Hospital Clinic i Provincial de Barcelona, Servicio de Oncologia
-
Madrid, España
-
Toledo, España
- Hospital Virgen de la Salud, Servicio Oncologia
-
-
-
-
California
-
La Jolla, California, Estados Unidos, 92093
- University of California San Diego Medical Center
-
-
Florida
-
Boynton Beach, Florida, Estados Unidos, 33435
- Palm Beach Institute of Hematology and Oncology
-
Miami, Florida, Estados Unidos, 33136
- University of Miami
-
-
Louisiana
-
Baton Rouge, Louisiana, Estados Unidos, 70809
- Medical Oncology LLC
-
-
Maryland
-
Annapolis, Maryland, Estados Unidos, 21401
- Annapolis Oncology Center
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Dana Farber Cancer Center
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Virginia G. Piper Cancer Center
-
-
New York
-
New York, New York, Estados Unidos, 10021
- Memorial Sloan Kettering Cancer Center
-
Syracuse, New York, Estados Unidos, 13210
- Regional Oncology Center
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97227
- Kaiser Permanente Northwest Region Oncology Hematology
-
-
South Carolina
-
Greenville, South Carolina, Estados Unidos, 29605
- Cancer Centers of the Carolinas
-
-
Tennessee
-
Knoxville, Tennessee, Estados Unidos, 37920
- Baptist Regional Cancer Center
-
Nashville, Tennessee, Estados Unidos, 37232
- Vanderbilt University Medical Center, Div. of Medical Oncology
-
-
Virginia
-
Lynchburg, Virginia, Estados Unidos, 24501
- Alan B. Pearson Regional Cancer Center Lynchburg Hematology Oncology Clinic
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Medical College of Wisconsin
-
-
-
-
-
Arkhangelsk, Federación Rusa
- State Institution of Healthcare "Arkhangelsk Regional Clinical Oncology Dispensary"
-
Ivanovo, Federación Rusa
- Regional Oncology Dispensary
-
Kazan, Federación Rusa
- Clinical Oncology Dispensary of Republic of Tatarstan
-
Kuzmolovo, Federación Rusa
- State Healthcare Institution "Leningrad Regional Oncologic Dispensary"
-
Moscow, Federación Rusa
- Non-state Healthcare Institution N.A. Semashko Central Clinical Hospital #2 of JSC "Russian Railway"
-
Obninsk, Federación Rusa
- Medical Radiology Research Center of Russian Medical Academy
-
Omsk, Federación Rusa
- State Healthcare Institution of Omsk Region "Clinical Oncologic Dispensary"
-
Saint Petersburg, Federación Rusa
- State Educational Institution "S.M. Kirov Military Medical Academy of Ministry of Defense of Russia"
-
St. Petersburg, Federación Rusa
- Saint Petersburg State Healthcare Institution "Municipal Clinical Oncology Dispensary"
-
-
-
-
-
Clermont-Ferrand, Francia
- CHU Estaing
-
Le Mans Cedex, Francia
- Centre Jean Bernard, Oncologie médicale
-
Lille, Francia
- Centre Régional de Lutte Contre le Cancer-Centre Oscar Lambret
-
Pessac, Francia
- Hôpital du Haut Lèvêque, Service d'Hepato Gastroentérologie
-
Poitiers Cedex, Francia
- Centre Hospitalier Universitaire de Poitiers
-
Rouen, Francia
- Hopital Charles Nicolle
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Pathologically confirmed metastatic adenocarcinoma of the pancreas (AJCC Stage IV). Subjects with islet cell neoplasms are excluded
- Non-measurable or measurable disease based on the RECIST criteria
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
- Life expectancy of > 3 months
Hematologic function, as follows:
- Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
- Platelet count ≥ 100 x 109/L
- Hemoglobin ≥ 9 g/dL (transfusion independent)
Renal function, as follows:
- Creatinine ≤ 2.0 mg/dL
Hepatic function, as follows:
- Aspartate aminotransferase (AST) ≤ 2.5 x ULN or ≤ 5 x ULN if known liver metastases.
- Alanine aminotransferase (ALT) ≤ 2.5 x ULN or ≤ 5 x ULN if known liver metastases
- Bilirubin ≤ 2 x ULN
- INR < 1.3 (or ≤ 3 if on warfarin for therapeutic anti-coagulation)
Exclusion Criteria:
Prior systemic therapy for metastatic pancreatic cancer
- Subjects who have received adjuvant treatment with gemcitabine and who had relapse metastatically are allowed
- Subjects with advanced local disease who have received treatment with gemcitabine and in whom progression has been observed with the onset of metastases less than 6 months are excluded
- Chemotherapy and/or radiation within 4 weeks of study enrollment
- Prior monoclonal antibody therapy within 60 days of study enrollment
- Known brain or leptomeningeal disease
History of other primary malignancy, unless:
- Curatively resected non-melanomatous skin cancer
- Other malignancy curatively treated with no known active disease present and no treatment administered for the last 3 years
- Active angina or Class III or IV Congestive Heart Failure (New York Heart Association CHF Functional Classification System)
- Use of any investigational product within 4 weeks of study enrollment
- Major surgery (that requires general anesthesia) within 4 weeks before study enrollment
- Women who are pregnant (confirmed by positive pregnancy test) or lactating
- Man or woman of childbearing potential not consenting to use adequate contraceptive precautions during the course of the study and for 4 weeks after the last AGS-1C4D4 and/or gemcitabine infusion administration
- Subject known to be human immunodeficiency, hepatitis B or hepatitis C virus positive
- Active serious infection not controlled with antibiotics
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador activo: 1. Gemcitabine monotherapy
|
IV infusion
|
Experimental: 2. Gemcitabine plus AGS-1C4D4
|
IV infusion
IV infusion
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
---|---|
Survival rate at 6 months
Periodo de tiempo: 6 months
|
6 months
|
Medidas de resultado secundarias
Medida de resultado |
Periodo de tiempo |
---|---|
Overall Survival (OS)
Periodo de tiempo: Throughout treatment period and post-treatment every 2 months until death, or subject discontinues the study
|
Throughout treatment period and post-treatment every 2 months until death, or subject discontinues the study
|
Progression free survival (PFS)
Periodo de tiempo: Throughout treatment period or post-treatment every 2 months until disease progression or death, respectively, or subject discontinues the study
|
Throughout treatment period or post-treatment every 2 months until disease progression or death, respectively, or subject discontinues the study
|
Change in level of serum tumor marker CA 19-9
Periodo de tiempo: Week 1, Week 4, Week 7 and every 3 weeks during the extended treatment period
|
Week 1, Week 4, Week 7 and every 3 weeks during the extended treatment period
|
Incidence of anti-AGS-1C4D4 antibody formation
Periodo de tiempo: Week 1, Week 7 and every 8 weeks during the extended treatment period
|
Week 1, Week 7 and every 8 weeks during the extended treatment period
|
Objective Response Rate (Partial Response or better per RECIST criteria version 1.1
Periodo de tiempo: Week 8, and every 8 weeks during the extended treatment period
|
Week 8, and every 8 weeks during the extended treatment period
|
Disease Control (Stable Disease or better per RECIST criteria)
Periodo de tiempo: Week 8, and every 8 weeks during the extended treatment period
|
Week 8, and every 8 weeks during the extended treatment period
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Director de estudio: Chief Medical Officer, Agensys, Inc.
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Enfermedades del Sistema Digestivo
- Neoplasias por tipo histológico
- Neoplasias
- Neoplasias por sitio
- Adenocarcinoma
- Carcinoma
- Neoplasias Glandulares y Epiteliales
- Enfermedades del sistema endocrino
- Neoplasias del Sistema Digestivo
- Neoplasias de glándulas endocrinas
- Neoplasias ductales, lobulillares y medulares
- Carcinoma Ductal
- Neoplasias pancreáticas
- Enfermedades pancreáticas
- Carcinoma Ductal Pancreático
- Efectos fisiológicos de las drogas
- Mecanismos moleculares de acción farmacológica
- Agentes antiinfecciosos
- Agentes Antivirales
- Inhibidores de enzimas
- Antimetabolitos, Antineoplásicos
- Antimetabolitos
- Agentes antineoplásicos
- Agentes inmunosupresores
- Factores inmunológicos
- Gemcitabina
Otros números de identificación del estudio
- 2008002
- 2009-009194-99 (Número EudraCT)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cancer de pancreas
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
-
Xinhua Hospital, Shanghai Jiao Tong University...Aún no reclutandoCANCER DE PROSTATA | Biopsia de próstataPorcelana